ArticleUrology2017

Expanding Immunotherapy Options for Bladder Cancer: Commentary on: Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

Jean-Michel Lavoie et al.PubMed ↗Publisher ↗

No numbers read from the abstract.